IP Library › Patent Application 19085658
Patent Application
App. No. 19/085,658

ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/085,658
Abstract

Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

Claims (59)

1 .- 61 . (canceled)

62 . A composition comprising a polynucleic acid, wherein the polynucleic acid comprises a sequence encoding a chimeric fusion protein (CFP), the CFP comprising:

(a) an extracellular domain;

(b) a transmembrane domain operatively linked to the extracellular domain; and

(c) an intracellular domain operatively linked to the transmembrane domain;

wherein the CFP comprises a sequence having at least 95% sequence identity to SEQ ID NO: 36.

63 . The composition of claim 62 , wherein the CFP comprises a sequence having at least 96% sequence identity to SEQ ID NO: 36.

64 . The composition of claim 62 , wherein the CFP comprises a sequence having at least 97% sequence identity to SEQ ID NO: 36.

65 . The composition of claim 62 , wherein the CFP further comprises a signal peptide and wherein the signal peptide comprises a sequence of MWLQSLLLLGTVACSIS (SEQ ID NO: 7).

66 . The composition of claim 62 , wherein the sequence of the polynucleic acid that encodes the CFP has at least 75% sequence identity to SEQ ID NO: 142.

67 . The composition of claim 62 , wherein the polynucleic acid comprises a sequence having at least 80% sequence identity to the coding sequence of SEQ ID NO: 142.

68 . The composition of claim 62 , wherein the polynucleic acid is an mRNA.

69 . The composition of claim 62 , wherein the polynucleic acid is associated with or is within a delivery vehicle, and wherein the delivery vehicle is a lipid nanoparticle.

70 . The composition of claim 62 , wherein the extracellular domain comprises:

(a) a heavy chain variable region (VH) that comprises:

(i) a heavy chain CDR1 (HCDR1) sequence according to SEQ ID NO: 253,

(ii) a HCDR2 sequence according to SEQ ID NO: 254, and

(iii) a HCDR3 sequence according to SEQ ID NO: 154; and

(b) a light chain variable region (VH) that comprises:

(i) a LCDR1 sequence according to SEQ ID NO: 255,

(ii) a LCDR2 sequence according to SEQ ID NO: 256, and

(iii) a LCDR3 sequence according to SEQ ID NO: 257.

71 . The composition of claim 70 , wherein the VH comprises a sequence with at least 98% sequence identity to SEQ ID NO: 4, and wherein the VL comprises a sequence according to SEQ ID NO: 5.

72 . The composition of claim 70 , wherein the extracellular domain comprises a GPC3 binding domain, wherein the GPC3 binding domain comprises a sequence having at least 95% sequence identity to SEQ ID NO: 6.

73 . The composition of claim 62 , wherein the extracellular domain comprises a sequence according to SEQ ID NO: 10.

74 . The composition of claim 62 , wherein the transmembrane domain comprises a sequence according to SEQ ID NO: 11.

75 . The composition of claim 62 , wherein the intracellular domain comprises a sequence according to SEQ ID NO: 12.

76 . The composition of claim 62 , wherein the CFP comprises a sequence according to SEQ ID NO: 407.

77 . A method of treating a GPC3-expressing cancer in a subject in need thereof comprising administering the subject the composition of claim 62 .

78 . A composition comprising a polynucleic acid, wherein the polynucleic acid comprises a sequence encoding a chimeric fusion protein (CFP), the CFP comprising:

(a) an extracellular domain;

(b) a transmembrane domain operatively linked to the extracellular domain; and

(c) an intracellular domain operatively linked to the transmembrane domain;

wherein the CFP comprises a sequence having at least 95% sequence identity to SEQ ID NO: 26.

79 . The composition of claim 78 , wherein the CFP comprises a sequence having at least 96% sequence identity to SEQ ID NO: 26.

80 . The composition of claim 78 , wherein the CFP comprises a sequence having at least 97% sequence identity to SEQ ID NO: 26.

81 . The composition of claim 78 , wherein the CFP further comprises a signal peptide and wherein the signal peptide comprises a sequence of MWLQSLLLLGTVACSIS (SEQ ID NO: 7).

82 . The composition of claim 78 , wherein the sequence of the polynucleic acid that encodes the CFP has at least 75% sequence identity to SEQ ID NO: 141.

83 . The composition of claim 78 , wherein the polynucleic acid comprises a sequence having at least 80% sequence identity to the coding sequence of SEQ ID NO: 141.

84 . The composition of claim 78 , wherein the polynucleic acid is an mRNA.

85 . The composition of claim 78 , wherein the polynucleic acid is associated with or is within a delivery vehicle.

86 . The composition of claim 85 , wherein the delivery vehicle is a lipid nanoparticle.

87 . The composition of claim 78 , wherein the extracellular domain comprises a TROP2 binding domain, wherein the TROP2 binding domain comprises:

(a) a heavy chain variable region (VH) that comprises:

(i) a heavy chain CDR1 (HCDR1) sequence according to SEQ ID NO: 259,

(ii) a HCDR2 sequence according to SEQ ID NO: 260, and

(iii) a HCDR3 sequence according to SEQ ID NO: 153; and

(b) a light chain variable region (VL) that comprises:

(i) a LCDR1 according to SEQ ID NO: 279,

(ii) a LCDR2 according to SEQ ID NO: 280, and

(iii) a LCDR3 according to SEQ ID NO: 281.

88 . The composition of claim 87 , wherein the wherein the VH comprises a sequence according to SEQ ID NO: 1, and wherein the VL comprises a sequence according to SEQ ID NO:

2.

89 . The composition of claim 87 , wherein the TROP2 binding domain comprises a sequence according to SEQ ID NO: 3.

90 . The composition of claim 78 , wherein the extracellular domain comprises a sequence according to SEQ ID NO: 10.

91 . The composition of claim 78 , wherein the transmembrane domain comprises a sequence according to SEQ ID NO: 11.

92 . The composition of claim 78 , wherein the intracellular domain comprises a sequence according to SEQ ID NO: 12.

93 . The composition of claim 78 , wherein the CFP comprises a sequence according to SEQ ID NO: 407.

94 . A method of treating a TROP2-expressing cancer in a subject in need thereof comprising administering the subject the composition of claim 78 .

Assignments (2)
CHANGE OF NAME Recorded Oct 15, 2025
From: MYELOID THERAPEUTICS, INC.
To: CREATE MEDICINES, INC.
Reel/Frame 073098/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2025
From: GETTS, DANIEL; WANG, YUXIAO
To: MYELOID THERAPEUTICS, INC.
Reel/Frame 070773/0616 →